RebrAIn raises 3.7 million euros to support the fight against Parkinson’s disease

Altaïr Avocats advised RebrAIn, a Bordeaux-based medtech company, in their €3.7 million fundraising. Founded in 2021, RebrAIn has developed a solution aimed at simplifying electrode placement in the brain for patients suffering from Parkinson’s disease or tremors.

The Bordeaux-based medtech RebrAIn, incubated at Chrysa-link and led by David Caumartin, Emmanuel Cuny, and Nejib Zemzemi, has developed an innovative technology based on artificial intelligence to improve Deep Brain Stimulation (DBS), a surgical intervention used notably to treat Parkinson’s disease.

Through a precise targeting method and a collaborative health data registry, this technology aims to simplify, standardize, and make DBS more accessible, which, until now, has only been used by 3% of eligible patients worldwide.

RebrAIn has completed a €3.7 million Seed funding round, led by Karista and supported by Nouvelle Aquitaine CO-Investment (NACO), a significant milestone for RebrAIn.

RebrAIn aims to accelerate its commercial development internationally, particularly in the United States, and to intensify its R&D efforts. The funds will also be used to expand RebrAIn’s team, with the recruitment of data scientists and sales personnel.
 

The parties involved in this transaction:

Altaïr Avocats supported RebrAIn on its corporate aspects with Sébastien Péronne, partner Marie Elgart, and Aude Idris, associates, complemented by the support of the IP/IT team composed of Christophe Héry, partner, and Albane Watine, associate.